A Class ACT: MUSC Immunologists are Optimizng Adoptive Cell Transfer for Antitumor Treatments

Researchers are using adoptive cell transfer (ACT) to reinforce the ranks of a patient’s own T cells—the body’s warriors—and train them to better target the patient’s cancer. ACT involves harvesting T cells from a patient; expanding, conditioning, and sometimes reengineering them in vitro; and then reinfusing them into the same patient where they can direct an antitumor response. 

More at Progressnotes, MUSC’s Medical Magazine